



**CSE: IN**  
**OTCQB: IMLFF**

Suite 350– 409 Granville ST  
Vancouver, BC, Canada V6C-1T2  
Tel: 604.669.7207  
Email: [info@inmedpharma.com](mailto:info@inmedpharma.com)  
[www.inmedpharma.com](http://www.inmedpharma.com)

**InMed Pharmaceuticals, Inc., Retains Tiberend Strategic Advisors, Inc.  
as its Investor Relations and Corporate Communications Counsel**

**Vancouver, BC – December 2, 2014-** InMed Pharmaceuticals Inc. ("InMed") (CSE: IN; OTCQB: IMLFF), a clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems, today announced that it has retained Tiberend Strategic Advisors, Inc. to manage its investor and corporate communications programs. Tiberend Strategic Advisors is a New York City-based full service strategic communications firm focused on serving publicly traded and emerging growth companies in the healthcare and life sciences industry.

Craig Schneider, President and CEO of InMed, said, "With our aggressive growth strategy for our product pipeline and fast-tracked drug development pathway, we are committed to maximizing the value of our company for our investors and other stakeholders. Tiberend Strategic Advisors' expertise, industry relationships and strategic counsel will enable us to increase our visibility within the life science investment and biotech communities."

"Tiberend Strategic Advisors will guide InMed in "best practice" investor and industry communications, including the initiation of quarterly investor conference calls and disclosure of quantitative and qualitative performance metrics," commented Gregory Tiberend, president and CEO of Tiberend Strategic Advisors.

**About InMed**

InMed is a clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed's proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company. For more information, visit [www.inmedpharma.com](http://www.inmedpharma.com)

**ON BEHALF OF THE BOARD**

**InMed Pharmaceuticals Inc.**

Craig Schneider  
President and Chief Executive Officer  
T: 604.669.7207  
F: 604.683.2506  
E: [info@inmedpharma.com](mailto:info@inmedpharma.com)

**Tiberend Strategic Advisors, Inc.**

Joshua Drumm, Ph.D. (Investors)  
[jdrumm@tiberend.com](mailto:jdrumm@tiberend.com)  
212-375-2664

Amy Wheeler (Media)  
[awheeler@tiberend.com](mailto:awheeler@tiberend.com)  
646-362-5750

### *Forward Looking Statements*

*This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.*

*Additionally, there are known and unknown risk factors which could cause InMed Pharmaceuticals actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein.*

*All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed Pharmaceuticals disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.*

*These risks and uncertainties include, among others, the possibility that clinical trials will not be successful, or be completed, or confirm earlier clinical trial results, risks associated with obtaining funding from third parties, risks related to the timing and costs of clinical trials and the receipt of regulatory approvals*

*NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.*